Evogliptin NEW

Price	$1520	$1980	$2500
Package	25mg	50mg	100mg

Supply Ability:	10g
Update Time:	2026-04-20

Product Details

Product Name: Evogliptin	CAS No.: 1222102-29-5
Supply Ability: 10g	Release date: 2026/04/20

Product Introduction

Bioactivity

Name	Evogliptin
Description	Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.
In vitro	Evogliptin (2.49 mM; 12 h) effectively suppresses mDPP4 (membrane DPP4) activity without impacting cytokine levels or cell viability in PWM-induced H9 Th1 cells, demonstrating selective inhibition of the enzyme. Furthermore, it mitigates inflammatory and fibrotic responses by promoting autophagy in ATG7 f/f -Cre+ mouse primary hepatocytes. This specificity and dual functionality underscore its therapeutic potential, as evidenced by cell viability assays in dose-dependent evaluations.
In vivo	Evogliptin, administered at doses of 100 and 300 mg/kg through animal feed once daily for ten weeks, has demonstrated antidiabetic effects in HFD/STZ mice by improving glucose intolerance and insulin resistance. This study involved male ICR mice, modeling HFD/STZ-induced diabetes, where evogliptin significantly reduced blood glucose levels starting from the second week, a reduction that was sustained throughout the 10-week period, especially at the 300 mg/kg dosage. Additionally, a significant decrease in HbA1c levels was observed at the 300 mg/kg dose, along with a dose-dependent reduction in 6-hour fasted blood glucose levels, showcasing its potential in diabetes management.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Inhibitors Related	Stavudine \| Aceglutamide \| Hemin \| Tamoxifen \| Cysteamine hydrochloride \| Guanidine hydrochloride \| Hydroxychloroquine \| Enzalutamide \| Paeonol \| Naringin \| Alginic acid \| Sildenafil citrate

Company Profile Introduction

TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds. 170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.